Dr.LipidDallas said:If two explanations both fit, the useful question is which one predicts something the other does not.
Agreed, with the usual condition: that holds for the average and this board is a collection of individuals. A population claim and a personal prediction are different things and get quoted interchangeably.
andrew_nyc said:ATTAIN trial (survodutide) context for liver and MASH: survodutide, a GLP-1/glucagon dual agonist, showed -18.7% body weight at 46 weeks in the Phase…
Genuinely useful, thank you. I had the facts and not the framework. Sending this to two other people who asked me the same thing last week.
Dr.LipidDallas said:If two explanations both fit, the useful question is which one predicts something the other does not.
Filing a mild objection. Mild because I might be wrong; an objection because nobody has addressed the case that does not fit. I think the framing smuggles in the conclusion. Ask it the other way round and the obvious answer reverses, which usually means the question is doing the work.
Certified reference materials, analytical reagents, and research-grade standards for peptide verification. Trusted by laboratories worldwide.
Shop Reference StandardsThe figures, for anyone assembling their own picture. For anyone reading later: the numbers in this thread are worth checking against a primary source before you act on them, including mine. Half the figures circulating in this community trace back to a secondary summary that dropped a qualifier.
Moderator note: two posts asking for a source have been merged into one. Please search the thread before asking again. Report rather than reply if it drifts again.